A Comprehensive Head-to-Head Comparison of Key Plasma Phosphorylated Tau 217 Biomarker Tests

Noelle Warmenhoven,Gemma Salvado,Shorena Janelidze,Niklas Mattsson-Carlgren,Divya Bali,Anna Orduna Dolado,Hartmut Kolb,Gallen Triana-Baltzer,Nicolas R. Barthelemy,Suzanne E. Schindler,Andrew J. Aschenbrenner,Cyrus A. Raji,Tammie L.S. Benzinger,John C. Morris,Laura Ibanez,Jigyasha Timsina,Carlos Cruchaga,Randall J Bateman,Nicholas J Ashton,Burak Arslan,Henrik Zetterberg,Kaj Blennow,Alexa Pichet Binette,Oskar Hansson

DOI: https://doi.org/10.1101/2024.07.02.24309629

2024-07-05

Abstract:Plasma phosphorylated-tau 217 (p-tau217) is currently the most promising biomarkers for reliable detection of Alzheimer′s disease (AD) pathology. Various p-tau217 assays have been developed, but their relative performance is unclear. We compared leading plasma p-tau217 tests using cross-sectional and longitudinal measures of amyloid-β (Aβ)-PET, tau-PET, and cognition as outcomes, and benchmarked them against cerebrospinal fluid (CSF) biomarker tests. Samples from 998 individuals (mean[range] age 68.5[20.0-92.5], 53% female) from the Swedish BioFINDER-2 cohort were analyzed. Plasma p-tau217 was measured with mass spectrometry (MS) assays (the ratio between phosphorylated and non-phosphorylated [%p-tau217WashU]and p-tau217WashU) as well as with immunoassays (p-tau217Lilly, p-tau217Janssen, p-tau217ALZpath). CSF biomarkers included p-tau217Lilly, and the FDA-approved p-tau181/Aβ42Elecsys and p-tau181Elecsys. All plasma p-tau217 tests exhibited high ability to detect abnormal Aβ-PET (AUC range: 0.91-0.96) and tau-PET (AUC range: 0.94-0.97). Plasma %p-tau217WashU had the highest performance, with significantly higher AUCs than all the immunoassays (Pdiff<0.007). For detecting Aβ-PET status, %p-tau217WashU had an accuracy of 0.93 (immunoassays: 0.83-0.88), sensitivity of 91% (immunoassays: 84-87%), and a specificity of 94% (immunoassays: 85-89%). Among immunoassays, p-tau217Lilly and plasma p-tau217ALZpath had higher AUCs than plasma p-tau217Janssen for Aβ-PET status (Pdiff<0.006), and p-tau217Lilly outperformed plasma p-tau217ALZpath for tau-PET status (Pdiff=0.025). Plasma %p-tau217WashU exhibited higher associations with all PET load outcomes compared to immunoassays; baseline Aβ-PET load (R2: 0.72; immunoassays: 0.47-0.58; Pdiff<0.001), baseline tau-PET load (R2: 0.51; immunoassays: 0.38-0.45; Pdiff<0.001), longitudinal Aβ-PET load (R2: 0.53; immunoassays: 0.31-0.38; Pdiff<0.001) and longitudinal tau-PET load (R2: 0.50; immunoassays: 0.35-0.43; Pdiff<0.014). Among immunoassays, plasma p-tau217Lilly was more strongly associated with Aβ-PET load than plasma p-tau217Janssen (Pdiff<0.020) and with tau-PET load than both plasma p-tau217Janssen and plasma p-tau217ALZpath (all Pdiff<0.010). Plasma %p-tau217 also correlated more strongly with baseline cognition (Mini-Mental State Examination [MMSE]) than all immunoassays (R2 %p-tau217WashU: 0.33; immunoassays: 0.27-0.30, Pdiff<0.024). The main results were replicated in an external cohort from Washington University in St Louis (n =219). Finally, p-tau217Nulisa showed similar performance to other immunoassays in subsets of both cohorts. In summary, both MS- and immunoassay-based p-tau217 tests generally perform well in identifying Aβ-PET, tau-PET, and cognitive abnormalities, but %p-tau217WashU performed significantly better than all the examined immunoassays. Plasma %p-tau217 may be considered as a stand-alone confirmatory test for AD pathology, while some immunoassays might be better suited as triage tests where positive results are confirmed with a second test.

What problem does this paper attempt to address?

The paper attempts to address the issue of comparing the performance of different plasma phosphorylated tau 217 (p-tau217) biomarker detection methods in Alzheimer's disease (AD) pathology detection. Specifically, the study compares various p-tau217 detection methods in identifying amyloid-beta (Aβ) and tau protein deposition as well as cognitive function abnormalities, and contrasts them with established cerebrospinal fluid (CSF) and imaging markers. Additionally, the study explores which plasma p-tau217 tests can be used as independent confirmatory tests or triage tests in clinical practice. Through these comparisons, the study aims to determine which detection method is most suitable for the diagnosis and monitoring of Alzheimer's disease.